Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit
November 12 2020 - 04:05PM
Business Wire
Now Commercially Available, Both NextSeq 1000 and NextSeq 2000
Sequencers Include Integrated Informatics and Loss-less Compression
Technology, Creating an Intuitive User Experience
. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach
of the NextSeq™ 2000 Sequencing System with the commercial
availability of the P3 high-output flow cell. The P3 flow cell
offers 1.1 billion reads in a single sequencing run, almost three
times more than previously available on Illumina’s mid-throughput
NextSeq sequencing portfolio, expanding the range of applications
that run on the system.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201112005974/en/
Now commercially available, Illumina's
NextSeq 1000 and NextSeq 2000 (shown here) Sequencers include
integrated informatics and loss-less compression technology,
creating an intuitive user experience. (Photo: Business Wire)
“The advanced yet affordable P3 flow cell for the NextSeq 2000
gives customers more capacity to increase the depth and breadth of
their projects and the ability to stretch their project budgets,
yielding deeper insights,” said Susan Tousi, Chief Product Officer
of Illumina. “We’re pleased to further instill customer confidence
with the highest data quality ever achieved at commercial launch.
Together with the on-instrument integration of our award-winning
informatics solution and loss-less compression software, customers
can extract actionable insights with a seamless user
interface.”
“At University of Edinburgh, our genomics work includes single
cell RNA sequencing projects which are often limited by cost,” said
Lee Murphy, Head of the Genetics Core at the Edinburgh Clinical
Research Facility. “With the NextSeq 2000 and P3 kits, we are
experiencing higher output enabling more complex, informative
studies which increases the value of our offerings to our world
class researchers.”
“The NextSeq 2000 has enabled us to bring sequencing in-house
that we would otherwise have to outsource,” said Bryan Venters,
Director of Genomic Technologies at EpiCypher, an epigenetic
technology company located in North Carolina. “This is critical
because it gives us control over our development pipeline. With the
release of the P3 cartridge, it will enable higher throughput
sequencing and faster turnaround times.”
The P3 flow cell is available in four configurations, including
100-, 200- and 300-cycles, delivering 110 Gb, 220 Gb, and 330 Gb
per run, respectively. In response to customer feedback, Illumina
is also launching a 50-cycle kit, targeting infectious disease,
small RNA, and spatial transcriptomics applications. Additionally,
at the outset of 2021, the NextSeq1000 and NextSeq 2000 platforms
will come with a tool designed to allow easy recycling of >60%
of the reagent cartridge used in each sequencing run.
Illumina also announced the commercial availability of the
NextSeq 1000, with an even more accessible price point for
sequencing up to 400 million reads per run. Like the NextSeq 2000,
the NextSeq 1000 offers onboard informatics for rapid secondary
analysis and cloud-based, loss-less compression technology – the
first of its kind to offer genomic compression technology built-in.
The systems were designed with customers in mind, offering not only
a clearer path to deep, actionable insights, but also our most
intuitive user experience yet.
“Both the NextSeq 1000 and NextSeq 2000 are designed to simplify
workflows and empower labs of any size with the economy of scale to
sequence more, more frequently,” said Mark Van Oene, Chief
Commercial Officer of Illumina. “With lower run costs, we’re
empowering our customers to more freely pursue their research ideas
and drive genomics forward.”
The NextSeq 1000 and NextSeq 2000, as well as the P2 and P3 flow
cells, are now shipping.
To learn more, visit our website.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and connect with us on Twitter,
Facebook, LinkedIn, Instagram, and YouTube.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties, including the expectation for lower costs
related to the storing and managing of genomic data costs. Among
the important factors that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services; (ii) our ability to deploy new products, services, and
applications, and to expand the markets for our technology
platforms; and (iii) the acceptance by customers of our newly
launched products, together with other factors detailed in our
filings with the Securities and Exchange Commission, including our
most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201112005974/en/
Media: Karen Birmingham, PhD 646-355-2111
kbirmingham@illumina.com
Investors: Juliet Cunningham 858-882-2171 ir@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2023 to Mar 2024